Daniel Benjamin Mark, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 2400 Pratt St, Durham, NC 27705
Phone (919) 668-8775
Email address mark0004@mc.duke.edu

Dr. Mark is a clinical cardiologist with the rank of Professor of Medicine (with tenure) as well as Vice Chief for Academic Affairs in the Division of Cardiology, Department of Medicine at Duke University Medical Center. He is also the Director of Outcomes Research at the Duke Clinical Research Institute. He has been on the full-time faculty at Duke since 1985. Prior to that he completed his cardiology fellowship at Duke, his residency and internship at the University of Virginia Hospital, and received his medical degree from Tufts University and his Master’s degree from Harvard. In 1998, he was given the honor of being elected to the American Society for Clinical Investigators and in 2002 he was honored by election to the Association of American Physicians. These organizations are the two most prestigious honor societies in academic medicine. In 2009, Dr. Mark was awarded the American College of Cardiology Distinguished Scientist Award.

Dr. Mark's major research interests include medical economics and quality of life outcomes, outcomes research, and quality of medical care. Currently, Dr. Mark is directing a number of outcomes analyses for ongoing clinical trials including PROMISE (anatomic versus functional testing for coronary artery disease, NIH), CABANA (catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation, NIH), ISCHEMIA (percutaneous coronary intervention versus optimal medical therapy for moderate-severe ischemia), and STICH (CABG +/- ventricular reconstruction versus medical therapy for ischemic heart disease, NIH). He was the principal author of the AHCPR Unstable Angina Guidelines and is a co-author of both the American College of Cardiology Guideline on Exercise Testing and their Coronary Stent Consensus Guideline. He is also the Editor of the American Heart Journal. Dr. Mark has published over 270 peer-reviewed articles, two books, and 80 book chapters. He lectures widely in the US, as well as in Canada, South America, and Europe.

Keywords: cost-effectiveness analysis, disease management, quality of life assessment, resource use.

Education and Training

  • M.D., Tufts University, 1978

Publications

Mark, Daniel B., Steen M. Hansen, Monique L. Starks, and Mary L. Cummings. “Drone-Based Automatic External Defibrillators for Sudden Death? Do We Need More Courage or More Serenity?.” Circulation 135, no. 25 (June 20, 2017): 2466–69. https://doi.org/10.1161/CIRCULATIONAHA.117.027888.

PMID
28630265
Full Text

Hoffmann, Udo, Maros Ferencik, James E. Udelson, Michael H. Picard, Quynh A. Truong, Manesh R. Patel, Megan Huang, et al. “Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain)..” Circulation 135, no. 24 (June 13, 2017): 2320–32. https://doi.org/10.1161/CIRCULATIONAHA.116.024360.

PMID
28389572
Full Text

Al-Khatib, Sana M., Gregg C. Fonarow, Jose A. Joglar, Lurdes Y. T. Inoue, Daniel B. Mark, Kerry L. Lee, Alan Kadish, Gust Bardy, and Gillian D. Sanders. “Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis..” Jama Cardiol 2, no. 6 (June 1, 2017): 685–88. https://doi.org/10.1001/jamacardio.2017.0630.

PMID
28355432
Full Text

Fanaroff, Alexander C., Stefan K. James, Giora Weisz, Kristi Prather, Kevin J. Anstrom, Daniel B. Mark, Ori Ben-Yehuda, Karen P. Alexander, Gregg W. Stone, and E Magnus Ohman. “Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial..” J Am Coll Cardiol 69, no. 18 (May 9, 2017): 2304–13. https://doi.org/10.1016/j.jacc.2017.02.056.

PMID
28473136
Full Text

Cowper, Patricia A., Shubin Sheng, Renato D. Lopes, Kevin J. Anstrom, Judith A. Stafford, Linda Davidson-Ray, Sana M. Al-Khatib, et al. “Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial..” Jama Cardiol 2, no. 5 (May 1, 2017): 525–34. https://doi.org/10.1001/jamacardio.2017.0065.

PMID
28355434
Full Text

Pokharel, Yashashwi, Khaja Chinnakondepalli, Katherine Vilain, Kaijun Wang, Daniel B. Mark, Glenn Davies, Michael A. Blazing, et al. “Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)..” Circ Cardiovasc Qual Outcomes 10, no. 5 (May 2017). https://doi.org/10.1161/CIRCOUTCOMES.116.003201.

PMID
28506979
Full Text

Fordyce, Christopher B., Pamela S. Douglas, Rhonda S. Roberts, Udo Hoffmann, Hussein R. Al-Khalidi, Manesh R. Patel, Christopher B. Granger, et al. “Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing: The PROMISE Minimal-Risk Tool, A Secondary Analysis of a Randomized Clinical Trial..” Jama Cardiol 2, no. 4 (April 1, 2017): 400–408. https://doi.org/10.1001/jamacardio.2016.5501.

PMID
28199464
Full Text

Shah, Rohan, Eric Yow, William Schuyler Jones, Louis P. Kohl, Andrzej S. Kosinski, Udo Hoffmann, Kerry L. Lee, et al. “Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial..” Am Heart J 184 (February 2017): 1–9. https://doi.org/10.1016/j.ahj.2016.10.014.

PMID
27892881
Full Text

Mark, Daniel B., Pamela S. Douglas, and Melanie R. Daniels. “Economic Outcomes With Anatomical Versus Functional Diagnostic Testing for Coronary Artery Disease..” Ann Intern Med 165, no. 12 (December 20, 2016). https://doi.org/10.7326/L16-0482.

PMID
27992905
Full Text

Pages